A decision-analytical model shows that everolimus has a favorable budget impact when introduced into the treatment algorithm for metastatic renal cell carcinoma.
Lee Stern, MS
Advertisement
Articles by Lee Stern, MS
Saxagliptin, in combination with metformin, provides a durable, well-tolerated, and cost-effective treatment option for patients with type 2 diabetes mellitus, from a US payer perspective.
Advertisement
Latest Updated Articles
- US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
Published: February 11th 2012 | Updated:
- Budget Impact of Everolimus in Treating Metastatic Renal Cell Carcinoma
Published: November 13th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
3
CHEST 2025: Advancing Respiratory Virus Vaccines and Improving Uptake Among High-Risk Populations
4
G-CSF is a Potential Alternative in Treatment of Hot Flashes in Postmenopausal Women
5
